Skip to main content
Clinical Trials/NCT04882618
NCT04882618
Unknown
Phase 4

Is the Extended Lymph Node Dissection Under Indocyanine Green (ICG) Based Fluorescence Imaging Superior to Conventional Extended Lymph Node Dissection During Laparoscopic Radical Prostatectomy(LRRP)?

TC Erciyes University1 site in 1 country50 target enrollmentStarted: November 8, 2019Last updated:

Overview

Phase
Phase 4
Enrollment
50
Locations
1
Primary Endpoint
pathology of indocyanine green positive lymph nodes

Overview

Brief Summary

Standard treatment of local or locally advanced prostate cancer is radical prostatectomy (RRP) surgery. During RRP in certain patients extended lymph node dissection (ELND) is recommended. to detect eligible patients for ELND some nomograms based on clinical factors of them is used. The Briganti nomogram is one of them. If the patient has 7% or more probability on Briganti nomogram, then ELND is recommended. But ELND is complicated surgical procedure and may cause labor lost and cost.

It is aimed here to show whether the ICG based fluorescence imaging during laparoscopy may yield higher accuracy to detect metastatic LNs than the conventional ELND?

Detailed Description

50 patients with diagnosis of local or locally advance prostate cancer and having LN invasion probability between 7-50% on 2018 Briganti Nomogram will be included to this study.

Before Laparoscopic radical prostatectomy (LRRP), ICG is injected left and right lobe of the propagate during cystoscopy.

Extended LND is performed in all patients. But before it, fluorescence imaging will be done, and ICG positive lymph nodes (LN) are dissected and sent pathology separately.

Positive LN yield pf ICG guided LND and conventional LND is compared.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Histologically confirmed locally limited prostate cancer;
  • Intermediate or high risk tumor
  • Recommended and planned prostatectomy;
  • Completed and signed written consent;
  • Voluntarily agreement to participate in this study
  • Age of the study participants ≥ 18 years.

Exclusion Criteria

  • Allergic reaction to active ingredient (indocyanine green);
  • Iodine allergy;
  • Hyperthyroidism;
  • High-grade renal impairment;
  • High-grade hepatic insufficiency;
  • Unwillingness to the storage and disclosure of pseudonymous disease and personal data
  • psychiatric pre-existing conditions or other circumstances that make a cooperation by the patient in question

Arms & Interventions

ICG group

Experimental

ICG injection before LRRP via cystoscopy

Intervention: Indocyanine green (Drug)

Outcomes

Primary Outcomes

pathology of indocyanine green positive lymph nodes

Time Frame: 15 day after surgery

İndocyanine green positvie lymph nodes are malign or benign

Total lymph node numbers of conventional extended lymph node dissection

Time Frame: 15 day after surgery

total number of dissected lymph nodes during conventional extended lymph node dissection

pathology of lymph nodes

Time Frame: 15 day after surgery

Pathology of material from conventional extended lymph node dissection

Indocyanine green postive lymph node numbers

Time Frame: 15 day after surgery

total number of dissected lymph nodes which are indocyanine green positive

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Abdullah Demirtas

MD, Professor in Urology

TC Erciyes University

Study Sites (1)

Loading locations...

Similar Trials